Comparison of the effect of Plasmalyte-A versus 0.9% normal saline as intravenous fluid therapy on serum bicarbonate levels in children with Dengue.
Phase 3
- Conditions
- Health Condition 1: A90- Dengue fever [classical dengue]Health Condition 2: A91- Dengue hemorrhagic fever
- Registration Number
- CTRI/2024/04/066542
- Lead Sponsor
- JAWAHARLAL NEHRU MEDICAL COLLEGE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Diagnosed cases of dengue based on clinical features and laboratory reports (including Dengue IgM,IgG and NS1 levels) requiring intravenous fluid therapy
Exclusion Criteria
(1)Comorbid conditions that may affect the outcome of the study like chronic liver disease, congenital heart disease, etc
(2) Allergies to Normal saline (0.9%) or Plasmalyte-A
(3)Patients with PeLOD-2 score of more than or equal to 14
(4) Refusal to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain Plasmalyte-A's impact on serum bicarbonate in Dengue-induced metabolic acidosis?
How does Plasmalyte-A compare to 0.9% normal saline in managing electrolyte disturbances during Dengue fluid resuscitation?
Which biomarkers correlate with improved bicarbonate levels in children with classical vs. hemorrhagic Dengue using balanced crystalloids?
What adverse events are associated with Plasmalyte-A versus normal saline in pediatric Dengue fluid therapy protocols?
Are there alternative balanced crystalloids or combination therapies showing superior acid-base correction in Dengue trials?